More than two-thirds of stroke survivors have upper extremity paresis (ie, motor impairment affecting the arms and hands),1 and this impairment is typically treated with some amount of rehabilitation therapy. One such example of intense, task-based therapy is modified constraint-induced movement therapy (mCIMT). Research in the field of upper extremity motor recovery after stroke is seeking to facilitate beneficial neuroplasticity by coupling intense rehabilitation with neurostimulation, thereby attempting to leverage endogenous mechanisms in the brain to improve outcomes.

tDCS at doses of 2 mA or 4 mA, in addition to mCIMT, did not lead to further reduction in motor impairment in patients 1–6 months after stroke, but it was safe, well tolerated, and feasible for clinical practice. tDCS at higher doses (ie, >4 mA) might be a consideration for future trials in addition to balancing known covariates affecting stroke recovery during the group allocation.

Over the past few months, investigative journalist Charles Piller has published—eg, in The Daily Mail, The New York Times, and Science—multiple reports of supposed historical fraud in Alzheimer's disease research. Now, in his book Doctored: fraud, arrogance and tragedy in the quest to cure Alzheimer's disease, Piller expands on these claims. A book that discusses why a scientist might consider fraud, and how it could be achieved, would be very welcome, but apart from mention of the difficulties faced by whistleblowers, Piller does not provide such analysis.

Allen JA, Lin J, Basta I, et al. Safety, tolerability, and efficacy of subcutaneous efgartigimod in patients with chronic inflammatory demyelinating polyradiculoneuropathy (ADHERE): a multicentre, randomised-withdrawal, double-blind, placebo-controlled, phase 2 trial. Lancet Neurol 2024; 23: 1013–24—In this Article, corrections have been made to definitions of safety populations in tables 1 and 3, the first footnote of table 1, and the indentation of “Atypical CIDP” row of table 1, and the appendix has also been corrected.